25 August 2017Big Pharma

Video interview: Regulatory issues key for life sciences in Brexit debate

With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
31 August 2017   The practical implications of Brexit, including on the Unified Patent Court, were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

More on this story

Big Pharma
31 August 2017   The practical implications of Brexit, including on the Unified Patent Court, were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

More on this story

Big Pharma
31 August 2017   The practical implications of Brexit, including on the Unified Patent Court, were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.